Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5356056 | 0.99 | PDE8B (0.33) | PDE8BCSNK2A1PIM1CSNK2A2CSNK2B | |
| SCHEMBL5356001 | 0.89 | CSNK2A1 (0.32) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL5354429 | 0.88 | CSNK2A1 (0.33) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL5368372 | 0.84 | CSNK2A1 (0.33) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL6672310 | 0.82 | PIM1 (0.30) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL3977357 | 0.81 | CSNK2A1 (0.44) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL14516597 | 0.80 | TLR7 (0.46) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL5367276 | 0.79 | HTR2A (0.38) | — | |
| Hydrochloric Acid SCHEMBL3971178 | 0.79 | TLR7 (0.45) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL5355562 | 0.79 | BCHE (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276515-B2 | Thioether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-6949649-B2 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050209268-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-09-22 | — | — | US | disclosed |
| EP-1451191-A1 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040097736-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-20 | — | — | US | disclosed |
| WO-2003050121-A1 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209268-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | PDE8B 4620/4885CSNK2A1 837/4885PIM1 480/4885 |
| US-20040097736-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | PDE8B 4620/4885CSNK2A1 837/4885PIM1 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.